Form 4: Xilio Therapeutics Executive Acquires Stock Options
SEC Filing
Kevin M. Brennan, SVP of Finance and Accounting at Xilio Therapeutics, acquired 26,000 stock options on October 1, 2024, exercisable at $0.75 per share.
Summary
- Kevin M. Brennan, SVP of Finance and Accounting at Xilio Therapeutics, filed a Form 4 on October 2, 2024, reporting a transaction.
- On October 1, 2024, Brennan acquired 26,000 stock options with an exercise price of $0.75.
- These options vest on September 30, 2025, contingent upon continued service to Xilio Therapeutics or its subsidiaries.
- Following the reported transaction, Brennan directly owns 26,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of stock option grant and transaction. |
| 10/02/2024 | Date of Form 4 filing. |
| 09/30/2025 | Vesting date for 100% of the stock options. |
| 09/30/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.